Well, hasn't your competent? doctor already prescribed various types of psychedelics to get you recovered?
What about all these drugs for stroke recovery? Doesn't your doctor read the literature AND create protocols from that research? NO? SO TOTALLY INCOMPETENT THEN?
DMT (8 posts to November 2020)
ecstasy (19 posts to November 2012)
LSD (5 posts to September 2018)
CerAxon (5 posts to January 2012)
citicoline (15 posts to October 2011)
magic mushrooms (10 posts to October 2014)
psilocybin (14 posts to May 2014)
My 13 reasons for marijuana use post-stroke.
Don't follow me, I'm not medically trained, and I don't have a Dr. in front of my name.
The latest here:
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects.
Author: Anna Komarczewska, ORCID: https://orcid.org/0009-0006-7378-2607
E-mail: lek.komarczewska@wp.pl
Rydygier Provincial Integrated Hospital in Toruń, Toruń, Kujawsko-Pomorskie, Poland
Filip Matusiak, ORCID: https://orcid.org/0009-0002-0538-6443
E-mail: f.matusiak98@gmail.com
Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Kujawsko-Pomorskie, PL
Klaudia Brzoza, ORCID: https://orcid.org/0009-0006-0950-4514
E-mail: klaudiabrzoza99@gmail.com
Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Kujawsko-Pomorskie, PL
Michał Kociński, ORCID: https://orcid.org/0009-0007-7651-7929
E-mail: michal.kocinski1999@gmail.com
Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Kujawsko-Pomorskie, PL
Patryk Iglewski, ORCID:https://orcid.org/0009-0004-6611-2168ttps://o
E-mail: patryk.iglewski01@gmail.com
Rydygier Provincial Integrated Hospital in Toruń, Toruń, Kujawsko-Pomorskie, Poland
Michał Pietrasz, ORCID: https://orcid.org/0009-0000-8148-7487
E-mail: michal.pietrasz252@gmail.com
Rydygier Provincial Integrated Hospital in Toruń, Toruń, Kujawsko-Pomorskie, Poland
Corresponding Author:
Anna Komarczewska lek.komarczewska@wp.pl
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in
controlled clinical settings, raising questions about biological mechanisms supporting
durability beyond the acute drug effect. [5,7] Mechanistic accounts increasingly focus on
neuroplasticity as a candidate pathway linking transient serotonergic receptor activation to
longer-lasting psychological and clinical change. [2,6] To synthesize evidence from the
2
publications regarding (1) antidepressant clinical outcomes after psilocybin-assisted
interventions and (2) neuroplasticity-related biological findings that plausibly support sustained
improvement. [2,3] Narrative review using only (clinical trials/secondary analyses and
mechanistic animal/neuroimaging work). Evidence was summarized qualitatively; no meta
analysis was performed. [2,16] Randomized and open-label clinical studies report rapid
symptom reduction and follow-up persistence in major depression and cancer-related
depression/anxiety, including six-month outcomes in treatment-resistant depression (TRD)
protocols with psychological support. [4,5,7,19] Preclinical work provides convergent evidence
of plasticity-relevant change after psilocybin, including structural synaptic remodeling in
frontal cortex and hippocampal plasticity-related outcomes in extinction learning paradigms.
[3,8] Human neuroimaging work reports changes consistent with altered large-scale brain
dynamics after psilocybin and TRD-related mechanistic findings on fMRI. [6,20] Across the
uploaded dataset, psilocybin-assisted therapy is associated with rapid antidepressant effects and
durability signals in selected samples, while convergent animal and human mechanistic
findings support neuroplasticity as a biologically plausible contributor to sustained clinical
improvement. [2,3]
No comments:
Post a Comment